Clinical effectiveness of GLP-1RA class drugs in weight reduction treatment.

doi:10.3877/cma.j.issn.2095-9605.2022.04.002

Abstract

Abstract:

Obesity and its metabolic problems have become a hot topic in clinical treatment. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are new hypoglycemic drugs in recent years, which can enhance insulin secretion and inhibit Glucagon secretion in a glucose concentration-dependent manner by activating GLP-1 receptor. At the same time, it can delay gastric empting, reduce food intake through central appetite suppression, so as to reduce blood glucose, reduce body weight and improve metabolism. In recent years, GLP-1RA has been reported to be used in clinical weight loss and hypoglycemia. Whether GLP-1RA can replace bariatric surgery in clinical practice is still unknown. This article will review the clinical application effect of GLP-1RA in weight loss.

Key words: Bariatric surgery, Glucagon-like peptide-1 (GLP-1), Glucagon-like peptide-1 receptor agonists (GLP-1RA), Diabetes, Obesity, Semaglutide

Ming He, Junming Chen, Yuan Zhang, Xiangxin Kong, Ke Song, Yixing Ren. Clinical effectiveness of GLP-1RA class drugs in weight reduction treatment.[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2022, 08(04): 225-230.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2022.04.002

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2022/V08/I04/225

References 30

[1]	Wang Y, Zhao L, Gao L, et al. Health policy and public health implications of obesity in China [J]. Lancet Diabetes Endocrinol, 2021, 9(7): 446-461.
[2]	Nauck MA, Quast DR, Wefers J, et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update [J]. Diabetes Obes Metab, 2021, 23(Suppl 3): 5-29.
[3]	Battelino T, Bergenstal RM, Rodriguez A, et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial [J]. Lancet Diabetes Endocrinol, 2022, 10(6): 407-417.
[4]	Wilding J, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity [J]. N Engl J Med, 2021, 384(11): 989-1002.
[5]	Lautenbach A, Wernecke M, Huber TB, et al. The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis [J]. Obes Surg, 2022, 32(10): 3280-3288.
[6]	Holst JJ. The physiology of glucagon-like peptide 1 [J]. Physiol Rev, 2007, 87(4): 1409-1439.
[7]	Hwang JI, Yun S, Moon MJ, et al. Molecular evolution of GPCRs: GLP1/GLP1 receptors [J]. J Mol Endocrinol, 2014, 52(3): T15-T27.
[8]	Strain WD, Frenkel O, James MA, et al. Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6 [J]. Stroke, 2022, 53(9): 2749-2757.
[9]	Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide [J]. Front Endocrinol (Lausanne), 2019, 10: 155.
[10]	Smits MM, Van Raalte DH. Safety of semaglutide [J]. Front Endocrinol (Lausanne), 2021,12: 645563.
[11]	Christou G A, Katsiki N, Blundell J, et al. Semaglutide as a promising antiobesity drug [J]. Obes Rev, 2019, 20(6): 805-815.
[12]	O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial [J]. Lancet, 2018, 392(10148): 637-649.
[13]	Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial [J]. JAMA, 2021, 325(14): 1403-1413.
[14]	Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial [J]. Lancet, 2021, 397(10278): 971-984.
[15]	Andreadis P, Karagiannis T, Malandris K, et al. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis [J]. Diabetes Obes Metab, 2018, 20(9): 2255-2263.
[16]	Gibbons C, Blundell J, Tetens HS, et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes [J]. Diabetes Obes Metab, 2021, 23(2): 581-588.
[17]	Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial [J]. Lancet, 2021, 398(10295): 143-155.
[18]	Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial [J]. Lancet Diabetes Endocrinol, 2022,10(6): 418-429.
[19]	Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity [J]. N Engl J Med, 2022, 387(3): 205-216.
[20]	Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes [J]. J Clin Endocrinol Metab, 2021,106(2): 388-396.
[21]	Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes[J]. N Engl J Med, 2021, 385(6): 503-515.
[22]	Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial [J]. Lancet, 2021,397(10271):293-304.
[23]	Ejarque M, Guerrero-Perez F, de la Morena N, et al. Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes [J]. Sci Rep, 2019, 9(1): 6274.
[24]	Larraufie P, Roberts GP, McGavigan AK, et al. Important role of the GLP-1 axis for glucose homeostasis after bariatric surgery [J]. Cell Rep, 2019, 26(6): 1399-1408.
[25]	Svane MS, Jorgensen NB, Bojsen-Moller KN, et al. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery [J]. Int J Obes (Lond), 2016, 40(11): 1699-1706.
[26]	Wallenius V, Dirinck E, Fandriks L, et al. Glycemic control after sleeve gastrectomy and Roux-en-Y gastric bypass in obese subjects with type 2 diabetes mellitus [J]. Obes Surg, 2018, 28(6): 1461-1472.
[27]	Webb DL, Abrahamsson N, Sundbom M, et al. Bariatric surgery - time to replace with GLP-1? [J]. Scand J Gastroenterol, 2017, 52(6-7): 635-640.
[28]	Zhang L, Tan WH, Chang R, et al. Perioperative risk and complications of revisional bariatric surgery compared to primary Roux-en-Y gastric bypass [J]. Surg Endosc, 2015, 29(6): 1316-1320.
[29]	Wharton S, Kuk JL, Luszczynski M, et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery [J]. Clin Obes, 2019, 9(4): e12323.
[30]	Pajecki D, Halpern A, Cercato C, et al. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery [J]. Rev Col Bras Cir, 2013, 40(3): 191-195.

Please choose a citation manager

Content to export